一分钟看懂
这是一项关于小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Gocatamig；I-DXd；Atezolizumab；Carboplatin；Etoposide；Rescue Medications，当前状态为招募中。登记地点显示中国北京、福州、广州、江门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Gocatamig；I-DXd；Atezolizumab；Carboplatin；Etoposide；Rescue Medications · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital ( Site 1604) · 北京
- Fujian Provincial Cancer Hospital ( Site 1607) · 福州
- Southern Medical University Nanfang Hospital ( Site 1608) · 广州
- Jiangmen Central Hospital ( Site 1611) · 江门
- Harbin Medical University Cancer Hospital ( Site 1606) · 哈尔滨
- The First Affiliated Hospital of Nanchang University ( Site 1610) · 南昌
- Shanghai East Hospital ( Site 1600) · 上海
- Sichuan Cancer hospital. ( Site 1609) · 成都
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602) · 杭州
- Taizhou Hospital of Zhejiang Province ( Site 1601) · 台州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- The main inclusion criteria include but are not limited to the following:
- * Has a histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC)
- * For participants receiving gocatamig + ifinatamab deruxtecan (I-DXd) in maintenance only:
- Completed 3 to 4 cycles of platinum + etoposide chemotherapy with concurrent approved anti-programmed cell death 1/Ligand 1 (anti PD-1/L1) as first line (1L) treatment of ES-SCLC within 6 weeks prior to enrollment
- No radiological disease progression per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
- No other prior systemic ES-SCLC therapy allowed
- Rechallenge therapy counts as an additional line and leads to exclusion
- * For participants receiving gocatamig + I-DXd in induction and maintenance, or gocatamig + I-DXd in induction followed by gocatamig + atezolizumab in maintenance, or carboplatin + etoposide + atezolizumab in induction followed by atezolizumab in maintenance: No prior systemic ES-SCLC treatment allowed
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07227597；登记信息更新于 2026-10-01；本站同步于 2026-10-08。